CML Publications

To keep you up-to-date on the latest scientific findings and on the clinical management of CML the iCMLf is pleased to present to you monthly updates from key CML publications in peer-reviewed journals. 

This month's iCMLf 'Publications of the month' are brought to you by Professor Timothy Hughes. From the many papers on CML published this month Professor Hughes has selected topical, interesting papers for your perusal including interesting articles from the emerging economic regions.

Read Professor Hughes' CML publications of the month: September 2019

Clinical publications

• Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
  Lauseker M et al. Am J Hematol, August 2019 (epub ahead of print)
• Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
  Baccarani M et al. Leukemia, August 2019 (epub ahead of print)
• Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study
  Cortes J et al. Leuk Lymphoma, August 2019 (epub ahead of print)
• Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
  Claudiani S et al. Haematologica, September 2019 (epub ahead of print)
• Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
  Naqvi K et al. Cancer, September 2019 (epub ahead of print)
• New approaches of molecular monitoring in CML (and other diseases)
  Radich J et al. Blood, September 2019 (epub ahead of print)
• Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy
  Efficace F et al. Leukemia, September 2019 (epub ahead of print)
• Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)
  Nagafuji K et al. J Hematol, September 2019 (epub ahead of print)

Scientific publications

• Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants
  Eide CA et al. Cancer Cell, September 2019 (epub ahead of print)
• De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
  Magistroni V et al. Haematologica, September 2019

Pediatric publications

• Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia
  Hijiya N et al. Blood, September 2019 (epub ahead of print)